Deucravacitinib (TYK2 inihibitor) already studied in PsO and PsA, has show efficacy in a phase 2 trial for treatment of SLE. Improvement in SRI(4), BICLA, LLADS, CLASI-50 and joint count Abs#1117 @RheumNow #ACR22 https://t.co/XElIuMmud9